Background: Several studies have investigated single nucleotide polymorphisms (SNP) in candidate genes associated with susceptibility, severity or outcome in patients with communityacquired pneumonia (CAP) with conflicting results. Methods: Multi-centre, prospective observational study. We studied 1162 white Spanish patients with CAP and 1413 controls. Severe forms of sepsis were recorded in 325 patients. Subjects were genotyped for the following polymorphisms: TNF À238 and À308, LTA þ252, IL6 À174, IL1RN 86 bp variable number of tandem repeats and TNFRSF1B þ 676 (TNFR2 M196R). Results: No significant differences in genotype or allele frequencies were seen among patients and controls. We did not find any association between TNF, LTA, IL6 and IL1RN polymorphisms with disease severity or outcome. Analysis of 28-day mortality showed a significant difference in the distribution of TNFRSF1B þ 676 G/T genotypes (p Z 0.0129). Sequential KaplaneMeier survival analysis of TNFRSF1B þ 676 G/T polymorphism showed a protective role of the GT genotype. Cox regression analysis adjusted for age, gender, hospital of origin and comorbidities showed that patients with GT genotypes had lower mortality rates compared to patients with GG or TT genotypes (p Z 0.02; HR 0.53; 95% CI 0.31e0.90 for 90-day survival; p Z 0.01; HR 0.41; 95% CI 0.21e0.81 for 28-day survival and p Z 0.049; HR 0.48; 95% CI 0.23e0.997 for 15-day survival). Conclusions: Our study does not support a role for the controversial studied polymorphisms of the TNF, LTA, IL6 and IL1RN genes in the susceptibility or outcome of CAP. A protective role of heterozygosity for the functionally relevant TNFRSF1B þ 676 polymorphism in the outcome of CAP was observed. ª
Introduction
The clinical presentation of community-acquired pneumonia (CAP) varies widely. 1 Several factors may play a role to account for this variability. Different pathogens, variable virulence in different strains of microorganisms, increasing age, and underlying diseases undoubtedly have an important impact, but genetic variability affecting the host response may also influence the susceptibility to it and the severity and outcome of infection. 2 Severe sepsis (SS) is common in hospitalized CAP patients, and is the leading cause of death in these patients. Since deregulation of innate immunity is believed to be central to the manifestation of sepsis, studies of genetic susceptibility and outcome of septic shock (SSh) have focused on genes involved in inflammatory pathways.
The need for early and definite diagnosis of sepsis, as well as the identification of patients at risk for poor prognosis, resulted in the proposition of a staging system: predisposition, insult, response and organ dysfunction (PIRO). 3 Several polymorphisms in cytokine genes have been associated with an increased risk of developing or dying from SSh, 4 and genetic variability has been suggested to be included as a new variable in the predisposition and response sections of PIRO. However, contradictory findings about the role of several genetic variants in sepsis have been reported, and it has usually been proved difficult to reproduce initial results. Several methodological problems may explain many of the discrepancies, including limited statistical power, heterogeneous populations with unrecognized confounding factors, misleading definition of phenotype, the presence of linkage disequilibrium, and the stratification of populations. 5 The aim of this multi-centre study was to recruit an ethnically homogeneous large group of patients with CAP in order to investigate whether common polymorphisms within genes encoding for inflammatory or anti-inflammatory molecules are associated with susceptibility, severity of illness or outcome in adult patients with CAP.
Methods

Patients and controls
A total of 1162 white Spanish patients with CAP, hospitalized at four university hospitals in Spain (Gran Canaria, Madrid, Valencia and Huesca) were prospectively included in the study. The diagnosis of pneumonia was based on the presence of acute onset of signs and symptoms suggesting lower respiratory tract infection on admission, and radiographic evidence of a pulmonary infiltrate that had no other known cause. Patients with defined severe immunosuppression, and patients with tuberculosis, obstructive pneumonia caused by neoplasia or pneumonia as terminal event of chronic and progressive disease, were excluded from the study. The control group consisted of 1413 unrelated healthy volunteers and patients without a previous history of relevant infectious diseases (49.04 AE 17.40 years, 43.1% women). Sepsis, SS, SSh and multiple organ dysfunction syndrome (MODS) were defined using the American College of Chest Physicians/Society of Critical Care Medicine criteria. 6 The pneumonia severity index (PSI) was measured using the Fine scale. 7 Acute respiratory failure (ARF) was defined as an oxygen saturation of less than 90% on room air, or a PaO 2 less than 60 mmHg. Acute respiratory distress syndrome (ARDS) was defined by using the American European Consensus Conference Definition. 8 In patients admitted on the intensive care unit (ICU), severity of illness was evaluated by the Acute Physiology and Chronic Health Evaluation (APACHE) II score, taking the worst reading of the first 24 h in the ICU. 9 
Genotyping
Genotypes for tumor necrosis factor-a (TNF ) À238 (rs 361525), TNF À308 (rs 1800629) and lymphotoxin-a (LT-a) þ252 (rs909253) were determined by real-time polymerase chain reaction as previously reported. 10 Genotyping for TNF receptor-2 (TNFRSF1B) þ676 (M196R; rs1061622), interleukin-6 (IL6) À174 (rs1800795) and the variable number of tandem repeat (VNTR) of 86 bp in interleukin-1 receptor antagonist (IL1RN; intron 2), were carried out using minor modifications of previously described procedures.
11e13 The accuracy of SNP genotyping was confirmed by direct sequencing in an ABI Prism 310 (Applied Biosystems) sequencer. Alleles of the VNTR 86 bp are termed according to the rank of frequencies in healthy individuals; alleles 1, 2, 3, 4 and 5 represent four repeats, two repeats, five repeats, three repeats and six repeats of 86 bp tandem repeat. Informed consent was obtained from the patients or their relatives. The protocol was approved by the local ethics committee of the four hospitals. Research that is reported in the manuscript is in compliance with the Helsinki Declaration.
Statistical analysis
HardyeWeinberg equilibrium for each single nucleotide polymorphism (SNP) and linkage disequilibrium (LD, D 0 ) was calculated with arlequin version 3.11 software. Quantitative variables are presented using arithmetic mean AE SEM. Genotype distribution was compared using c 2 test or Fisher exact test when needed, and odds ratios (OR) with 95% of confidence intervals (95% CI) were calculated. The relation between severity or outcome with genotypes was evaluated by binary logistic regression models. Age, gender, hospital of origin and co-morbidities were included as independent variables for multivariate analysis. Survival rates were estimated using the KaplaneMeier method and their comparison related to genotypes was performed with logrank test. Multivariate analysis adjusted for age, gender, hospital of origin and co-morbidities was carried out with Cox proportional hazard model. Statistical analysis was performed using SPSS 15.0 (SPSS, Inc, Chicago, IL).
Results
Between January 2002 and September 2007, patients admitted to four different Spanish University Hospitals were evaluated for the diagnosis of CAP. After excluding those patients without informed consent, those with ethnicity other than white Spanish, and those who fulfilled the exclusion criteria, a total of 1162 patients were finally included. The main demographic and clinical variables of the patients are showed on Table 1 .
Microbiological documentation of CAP was achieved in 614 patients (55.6%) Streptococcus pneumoniae was the most common etiologic agent (288, 26%; 46.9% of the patients with known causative microorganism), Pseudomonas aeruginosa was isolated in 26 patients (2.4%), Haemophilus influenzae in 17 (1.5%) and Staphylococcus aureus in 19 (1.7%). Other causative microorganisms were identified in 264 patients. One hundred and seven patients (9.2%) had positive blood cultures.
Empirical antibiotic therapy was according to ATS/IDSA guidelines in 95.5% of the patients. The mortality of these patients was 4.16% compared to 7.17% in those without guidelines adherence. No differences in appropriate antibiotic use were observed when stratifying patients based on severity or outcome: SS and SSh, 95.2 and 93.0%, respectively; ARF, 95.6%, ARDS 97.7%; and 90-day mortality 98.6%.
Distribution of genotypes of the 1162 patients and controls are summarized in Table 2 . Genotype frequencies of the studied polymorphisms in the control group were in HardyeWeinberg equilibrium. No significant differences in genotype or allele frequencies were seen between the two groups. We did not find either any association between TNF, LTA, IL6 and IL1RN polymorphisms with disease severity or outcome (Table 3) , even when severe forms of sepsis (N Z 325) were considered (data not shown). A trend toward LTA þ252 A homozygous individuals to MODS (p Z 0.048, OR Z 1.44, 95% CI 0.99e2.12) was observed. The TNF À308 and À238 and the LTA þ252 single nucleotide polymorphisms (SNP) were found to be in LD in the control group (D 0 for the SNP pairs TNF À238/À308, TNF À238/LTA þ252 and TNF À308/LTA þ252 were 0.87, 0.79 and 0.85, respectively (p < 0.001 for the three analysis). No association with susceptibility or outcome was observed when allelic and genotypic frequencies of the combined TNF and LTA SNPs were compared (data not shown).
When the TNFRSF1B þ 676 SNP was analysed, carriage of the G allele was found to be increased in patients who developed MODS (Table 3 ) and ARDS (data not shown), although the differences did not achieve statistical significance (p Z 0.048, OR Z 1.43, 95% CI 0.98e2.07 and p Z 0.085, OR Z 1.68, 95% CI 0.88e3.21, respectively). In the 28-day mortality analysis, a statistically significant difference in the distribution of TNFRSF1B þ 676 G/T genotypes was observed (p Z 0.0129 for the 3 Â 2 analysis). However, a protective role against fatal outcome of the heterozygous genotype, compared to homozygosity for the T and G alleles was now found (p Z 0.006, OR Z 0.39, 95% CI 0.17e0.8 and p Z 0.026, OR Z 0.55, 95% CI Z 0.30e0.95 for 28-and 90-day mortality, respectively). In fact, an increased frequency of individuals homozygous for both alleles was observed among non-survivors compared to survivors, although these differences did not achieve statistical significance (p Z 0.046, OR Z 1.83, 95% CI 0.98e3.6, and p Z 0.18 for homozygosity for T and G alleles vs the rest of genotypes, respectively). Due to the apparently contradictory results in the susceptibility to MODS and ARDS to the predisposition to fatal outcome, we first analysed 28-day death among individuals with MODS and ARDS (data not shown). Heterozygosity for TNFRSF1B þ 676 was found to be protective against 28-day death in patients with MODS (p Z 0.02, OR Z 0.36, 95% CI 0.13e0.91), and a non-significant trend was observed in patients with ARDS (p Z 0.037, OR Z 0.22, 95% CI 0.03e1.12). A predisposition to mortality among MODS patients was found to be associated with homozygosity for the G allele (p Z 0.02, OR Z 5.92, 95% CI 1.06e39.72); homozygosity for the T allele was also found to be increased in patients who died, although these differences did not achieve statistical significance. A similar distribution of genotypic frequencies was observed in patients with ARDS, although due to the small number of patients, no significant association of the individual homozygous genotypes with mortality was observed. We then conducted a sequential KaplaneMeier survival analysis of the three different TNFRSF1B þ 676 genotypes in the complete group of CAP patients at 15, 28 and 90 days (Figure 1 ). Cox regression analysis adjusted for age, gender, hospital of origin and comorbidities showed that patients with GT genotypes had lower mortality rates compared to those patients with GG þ TT genotypes (p Z 0.02, HR 0.53, 95% CI 0.31e0.90 for 90-day survival; p Z 0.01, HR 0.41, 95% CI 0.21e0.81 for 28-day survival and p Z 0.049, HR 0.48, 95% CI 0.23e0.997 for 15-day survival).
Discussion
In this study, we have observed a significantly lower frequency of individuals heterozygous for the TNFRSF1B þ 676 T/G SNP among those with fatal outcome compared to survivals, thus supporting a potential role of this polymorphism in the pathophysiology of CAP. To our knowledge this is the first report studying the role of TNFRSF1B alleles in patients with CAP. On the other hand, we did not confirm previous associations of the studied polymorphisms of TNF, LTA, IL6 and IL1RN with susceptibility to or severity and outcome of CAP.
Seminal studies in mice showed the key role of cytokines in sepsis.
14 In humans, conflicting results have been reported for TNF, LTA, IL6 and IL1RN polymorphisms in sepsis: TNF À308 and À238 were associated to disease severity and outcome in some studies 15e18 but not in others.
19e22 Controversy also exists regarding the role of the LTA þ252 20,23e25 and IL6 À174. 25e28 The IL1RN*2 allele has been reported to be associated with susceptibility or poor * For age the value is media AE standard deviation. y Some patients had more than one co-morbidity. CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; Non-severe sepsis, patients without either severe sepsis or septic shock; MODS, multiple organ dysfunction syndrome. Values are the number (%). N, number of patients. CAP, community acquired pneumonia. Gene nomenclature: TNF, tumor necrosis-a; LTA, lymphotoxin-a; TNFRSF1B, tumor necrosis factor alfa receptor-2; IL1RN VNTR, variable number of tandem repeat in interleukin-1 receptor antagonist; IL6, interleukin-6.
outcome of sepsis. 23,29e30 However, a non-significant decrease of homozygosity for the IL1RN*2 allele was even observed among non-survivors in our survey. These results were not replicated in our study, and even a non-significant association of homozygosity for the LTA þ252 A allele with the development of MODS was observed.
As far as we know, only three studies focusing on these genes have been conducted in CAP patients so far. Waterer et al. 16, 24 in two studies conducted in a relatively small group of patients found that homozygosity for the LTA þ252 A allele was a risk factor for SSh, whereas respiratory failure, in the absence of shock, strongly correlated with homozygosity for the LTA þ252 G allele. Gallagher et al. 25 did not find any association of the SNPs TNF À308 and IL6 À174 SNPs with susceptibility and severity. Possible explanations for the discrepancies include limited statistical power, heterogeneous patient populations with unrecognized confounding factors, and stratification of population substructure and/or imprecise definitions of phenotype. These limitations, evident in many of the above-mentioned studies, rendered their interpretation problematic. Compared to previous works, our study has several strengths. First, our large cohort of patients with CAP reduces the type I error. Second, the prospective design helps minimize phenotype misclassification. Third, we performed a multicenter study including only adult Spaniard Caucasian patients and controls. Fourth, genetic data were compared not only between patients and healthy controls, but also, and even more importantly, between patients with and without the studied clinical phenotypes. Fifth, whereas most of the aforementioned studies involved a mixed group of critically ill patients with sepsis, we have studied hospitalized patients with the only diagnosis of CAP. Data are number of patients and percentage. N, number of patients with available data; NSS, non-severe sepsis; SS, severe sepsis; SSh, septic shock; MODS, multiple organ dysfunction syndrome. Gene nomenclature: TNF, tumor necrosis-a; LTA, lymphotoxin-a; TNFRSF1B, tumor necrosis factor alfa receptor-2; IL1RN VNTR, variable number of tandem repeat in interleukin-1 receptor antagonist; IL6, interleukin-6. Finally, we have also evaluated the impact of the genetic variants in the severity and CAP mortality after controlling for different confounding variables already known to affect outcome.
In our sequential study of death associated to TNFRSF1B þ 676 genotypes, we have observed a significant association when 15-, 28-and 90-day mortality was studied.
TNFR1 and TNFR2 receptors mediate biological activity of TNF-a and LT-a. Both receptors activate distinct signal transduction pathways, which may explain their shared and diverse functions. 31 TNFR2 signalling is not well characterized, but it has been shown to mediate signals that promote tissue repair and angiogenesis. 31 In addition, a role of TNFR2 in apoptosis, cell activation, migration or proliferation in cultured cells has been reported. 31e32 Under certain circumstances, TNFR2 may also contribute to TNFR1-mediated proinflammatory responses. Several studies have reported an association of the TNFRSF1B þ 676 SNP with susceptibility to several inflammatory diseases such as systemic lupus erythematosus, 33 rheumatoid arthritis, 34 and Crohn's disease in humans. 35 Moreover, a recent study has found an association between the TNFRSF1B þ 676 SNP and response to infliximab. 36 The TNFRSF1B þ 676 SNP results in a change of methionine to arginine at codon 196 (M196R) located in close proximity to the proteolytic cleavage site, which is crucial for the shedding of TNFR2, and could condition soluble TNFR2 levels. 37, 38 In addition, the TNFR2-196R variant, encoded by the G allele, was shown to have a lower capacity to induce direct NF-kB signalling via TNFR2, leading to a diminished induction of NF-kB-dependent target genes involved in antiapoptotic and pro-inflammatory functions. 39 Our study suggests a protective role of heterozygosity at the TNFRSF1B þ 676 SNP in the outcome of CAP. However, homozygosity for the wild-type TNFRSF1B þ 676 T allele was associated with a trend towards protection from the development of MODS. Increased levels of NF-kB activation have been associated with a worse outcome from sepsis. 40, 41 Likewise, in our experience, TLR-mediated primary immunodeficiencies (PID) such as IRAK-4 and MyD88 deficiencies, leading to decreased NF-kB activation, confer a high susceptibility to invasive infections by S. pneumoniae and S. aureus, and in a lesser extent to P. aeruginosa. 42, 43 However, patients with these PID show a low clinical and biological inflammatory response in the course of the infections, and in fact their condition has been referred to as septicaemia without sepsis. 42, 43 The protective role of heterozygosity at TNFRSF1B þ 676 in the outcome of sepsis could thus be due to a counterbalance of the deleterious consequences of excessive or impaired NF-kB activation conferred by the genotype homozygous for the wild-type or mutant alleles, respectively. 44 To date only one study 20 has investigated the role of TNFR2 receptor polymorphisms (þ676 and þ1663) in 213 patients with severe sepsis. The authors found a positive correlation between increasing soluble TNFR1 and TNFR2 levels and organ dysfunction, but there was no influence of TNFRSF1B SNPs either on soluble TNFR2 levels or in susceptibility to and outcome from sepsis. Possible reasons for the discrepancy with the data from Gordon et al. 21 are the clinical phenotype and their smaller sample size.
In spite of the above-mentioned strengths of our study, we acknowledge some limitations. First, although current recommendations for treatment of sepsis and septic shock were applied, a common protocol was not specifically used. Second, only six polymorphisms of five mediators were determined. The functional importance of many of these polymorphisms remains to be elucidated, and many SNPs may simply represent genomic markers for other more functionally relevant genetic variants in linkage disequilibrium. Third, although our study could be underpowered to detect statistically significant differences for the less frequent genotypes, particularly in small subgroups or patients, a substantial number of patients (325, 28%) developed severe forms of sepsis. Nevertheless the sample size is sufficient to detect odds ratios of 1,49, 1,38, 1,29, 1,27 and 1,28 for the TNF À238 A, TNF À308 A, LTA þ252 G and, IL6 À174 and IL1RN*2 alleles respectively at a significance threshold of 0.05 with 80% power. These are the alleles previously reported to be involved in sepsis severity, usually with higher OR. In addition, when the association of TNFRSF1B þ 676 G/T genotype with 28-day mortality was analysed, the statistical power for the observed oddratio, with a significance level of 5%, was 93%. Despite all these limitations, this study is unique in having an ethnically homogeneous population of patients admitted to the hospital with CAP, and evaluating the factors associated with severity and mortality from the time of their admission to the hospital.
In conclusion, our study does not support a role of the controversial polymorphisms of TNF, LTA, IL6 and IL1RN in CAP and sepsis, at least in our population. However, it points towards a role of the TNFRSF1B þ 676 SNP in CAP outcome, which could potentially identify a subgroup of patients who may benefit from standard TNF-a and LTa modulatory therapies. 5/06), Ayoze García-Saavedra was supported by a grant from the Cabildo de Gran Canaria (Grant Tomas de Zarate 15725). 
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